Lipid Metabolism and Cardiac Test Markers: Importance of ...

More documents

Recommendations

Info

Adoption of Documents into Accreditation Process – Example of Crosswalk 14
CLSI Members & Volunteers Diverse representation from three constituencies Industry Government Professions IVD Manufacturers Public Health Agencies Hospitals and Laboratories LIS Vendors Regulatory Bodies Healthcare Delivery Systems Startup Companies Accrediting Organizations Educational Institutions Suppliers Others Professional Societies Trade Organizations 15
Page 1 and 2: Lipid Metabolism and Cardiac Test M
Page 3 and 4: Our Common Goal: Quality Healthcare
Page 5 and 6: CLSI Name Name change in 2005 to re
Page 7 and 8: CLSI’s Mission To develop best pr
Page 9 and 10: CLSI Consensus Process Government B
Page 11 and 12: CLSI products • Standards • Gui
Page 13: Use of CLSI Documents • Regulator
Page 17 and 18: Global Health Partnerships • Gran
Page 19 and 20: Global Health Partnerships Current
Page 21 and 22: CLSI’s Key Global Activities Inte
Page 23 and 24: Standards and Guidelines 23
Page 25 and 26: Why do Standards Matter? • Raise
Page 27 and 28: Standard or Guideline? • A standa
Page 29 and 30: Reasons for testing • To identify
Page 31 and 32: Standardization of Laboratory Resul
Page 33 and 34: Traceability in Laboratory Medicine
Page 35 and 36: Standardization vs. Proficiency Tes
Page 37 and 38: When and Why Is Traceability Most I
Page 39 and 40: Calibration Traceability Scheme Pri
Page 41 and 42: Reference Measurement Procedure, HD
Page 43 and 44: Beta-quantification limitations •
Page 45 and 46: Routine Method SIGNAL Trueness (acc
Page 47 and 48: Lipids: method evaluation • Inter
Page 49 and 50: Homogeneous HDL-C: approach 1 Step
Page 51 and 52: Homogeneous LDL-C: analogous to HDL
Page 53 and 54: Why is standardization important cl
Page 55 and 56: Comparison of HDL and LDL Cholester
Page 57 and 58: Comparison of HDL and LDL Cholester
Page 59 and 60: National Academy of Clinical Bioche
Page 61 and 62: NACB LMPG: Biomarkers of Acute Coro
Page 63 and 64: Risk Stratification of Acute Corona
Page 65 and 66:
NACB Recommendations (Con’t) •
Page 67 and 68:
Death or MI Troponin as a Marker of
Page 69 and 70:
Limitations of Troponin • Not an
Page 71 and 72:
FDA Approved Cardiac Troponin Assay
Page 73 and 74:
Limitations of Myoglobin • Can be
Page 75 and 76:
NACB Recommendations-BNP • Plasma
Page 77 and 78:
BNP and NT-proBNP - NACB Recommenda
Page 79 and 80:
Emerging Risk Factors for Cardiovas
Page 81 and 82:
Inflammation Biomarkers and Cardiov
Page 83 and 84:
Apolipoproteins A-I and B and Cardi
Page 85 and 86:
Homocysteine (Hcy) and Cardiovascul
Page 87 and 88:
NACB LMPG Point of Care Testing (Pu
Page 89 and 90:
NACB Guideline Recommendations-”E
Page 91 and 92:
Summary • CLSI is an internationa
Page 93:
THANK YOU FOR YOUR ATTENTION 93
show all

Lipid Metabolism and Cardiac Test Markers: Importance of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?